Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

@article{Schneeweiss2012ComparativeEA,
  title={Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.},
  author={Sebastian Schneeweiss and Joshua J Gagne and A Robertson Patrick and Niteesh K Choudhry and Jerry Avorn},
  journal={Circulation. Cardiovascular quality and outcomes},
  year={2012},
  volume={5 4},
  pages={
          480-6
        }
}
BACKGROUND Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation. We sought to compare the efficacy and safety of the 3 new agents based on data from their published warfarin-controlled randomized trials, using the method of adjusted indirect comparisons. METHODS AND RESULTS We included findings from 44 535 patients enrolled in 3 trials of the… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 69 CITATIONS, ESTIMATED 36% COVERAGE

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

Advisory Committee Briefing Document: Dabigatran Etexilate (DE), DE 150 BID and DE 110 BID

Boehringer Ingelheim
  • 2010

Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa, Canada: Canadian Agency for Drugs and Technologies

SA Wells GA Sultan, L Chen, M Khan, D. Coyle
  • 2009